Yahoo Finance Controlled Substance Market Report Up to 2031: Visiongain Research Inc
Visiongain has published a new report on Controlled Substance Market Report 2021-2031: Forecasts by Drug (Opioids, Stimulants, Depressants, and Cannabinoids), by Application (Attention-Deficit/Hyperactivity Disorder (ADHD), Pain Management, Depression, Sleep Disorder, Cough Suppression, Anxiety, Seizure, and Others), by Drug Type (Generic Drugs, and Branded Drugs), by Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), by End User (Hospitals, Homecare, Specialty Clinics, and Others), by Distribution Channel (Institutional Sale, and Retail Sales) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/controlled-substance-market-2021/#download_sampe_div
COVID-19 Impact on Controlled Substance Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Controlled Substance market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Market Drivers
Increasing Prevalence of Chronic Pain
Chronic pain is pain which lasts longer than six months and can occur from post-surgery, arthritis, back pain, headaches, muscle strains and sprains, repetitive stress injuries, fibromyalgia, nerve damage, lyme disease, broken bones, cancer, and among others. Controlled substances (opioids) are majorly recommended for patients associated with advanced cancer for reduction of the discomfort caused due to a diverse group of pain syndrome. Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.
Increasing Geriatric Population around the World
Geriatric population are at high risk of developing high chronic pain due to bone loss, Nerve damage. Muscle strains due to decreased immunity. Geriatric population requires controlled substance for the treatment of the chronic pain. Number of geriatric population is increasing very rapidly around the world. For instance: According to United Nations, Department of Economic and Social Affairs, Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Continuous increase in number of the geriatric population around the world is increasing demand for controlled substance around the world. Due to which increasing geriatric population around the world is working as a driver for the controlled substance market.
Market Opportunities
Increasing Strategic Agreements in Cholesterol Lowering Drugs market
Manufactures present in the market are performing various strategic agreements such as product launches or regulatory licenses/approval, acquisitions & merger, new product launches in order to expand their product portfolio with most credible credentials and advanced therapeutic products in the market focus segment. These strategic agreements are expected to create various opportunities in controlled substance market.
Get Detailed TOC @ https://www.visiongain.com/report/controlled-substance-market-2021/#download_sampe_div
Increasing research and development in Controlled Substance
Increasing prevalence of attention-deficit/hyperactivity disorder (ADHD), chronic pain, depression, sleep disorder, cough suppression, anxiety, seizure is leading various manufactures to increase their research and development activities for cholesterol lowering drugs. Research and development activities to increase therapeutic advance and to reduce side effects associated with controlled substance is expected to increase demand of cholesterol lowering drugs.
Competitive Landscape
Other companies profiled in the report include: Sun Pharmaceutical Ltd., Ampac Fine Chemicals, GW Pharmaceuticals plc, Merck & Co., Inc., Depomed, Inc., Coating Place, Inc., Corium International, Inc., Johnson and Johnson Services, Inc., Alkermes plc, Pfizer, Inc. and Orbis Biosciences, Inc.among others Some of the key developments are listed below:
• In 2020, Trevena Inc. has received U.S. Food and Drug Administration approval for Olinvyk (oliceridine), which is an opioid used in acute pain management from moderate to severe in adults. The new product approval is expected to help company in revenue generations from the market focus segments.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Controlled substances market and leading companies. You will find data, trends and predictions.
Find more Visiongain research reports on Therapeutic Drugs Sector click on the following links:
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports mean that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Web: https://www.visiongain.com
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.
